Pharmacodynamics of cefepime in patients with Gram-negative infections
Cefepime
Pharmacodynamics
DOI:
10.1093/jac/dkf130
Publication Date:
2002-08-30T20:38:44Z
AUTHORS (1)
ABSTRACT
We conducted a prospective, open-label study to delineate relationship between exposure and outcomes in 36 patients treated with cefepime. Twenty had documented Gram-negative infections. Timed blood urine samples were obtained at steady state determine pharmacokinetic pharmacodynamic parameters. Microbiological success was significantly correlated the proportion of dosing interval that cefepime concentrations exceeded 4.3 × MIC. Our results support vitro data suggest bactericidal activity β-lactams is optimized ∼4 These should be validated by large prospective clinical trials.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (225)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....